Top

Published in:

01-06-2013 | Geriatric Urology (TJ Guzzo, Section Editor)

Urinary Incontinence: Diagnosis and Treatment in the Elderly

Authors: Joy A. Greer, Lily A. Arya, Ariana L. Smith

Published in: Current Geriatrics Reports | Issue 2/2013

Abstract

Urinary incontinence is a prevalent condition among the elderly. History and physical exam are helpful in delineating the specific type or types of urinary incontinence present. When beginning treatment, clinicians should consider functional status, comorbidity, and goals of therapy. Therapeutic options include behavioral therapy, physical therapy, pharmacologic management, neuromodulation, mechanical devices, and surgery. The treatment options with the most data in the elderly are behavioral therapy and antimuscarinic medications, both showing effectiveness. Limited data are available for the other modalities, but generally show that they are effective in older patients. In this update, data from many recent meta-analyses and systematic reviews are synthesized to help guide treatment decisions for elderly patients suffering from urinary incontinence.

• Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21:5–26. This consensus statement provides consistent terminology to enable clinicians to communicate more effectively regarding care of patients with UI. CrossRef

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14. discussion 1314-5.PubMedCrossRef

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.PubMed

Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6:S574–9.PubMed

Hunter KF, Glazener CM, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 20007;(2):CD001843.

• Sandhu JS. Treatment options for male stress urinary incontinence. Nat Rev Urol. 2010;7:222–8. This review article succinctly described options for treatment of male SUI to give primary care clinicians an overview when referring patients for specialty treatment. PubMedCrossRef

•• Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40. This consensus statement provides clinicians with algorithms for treating both men and women with UI. PubMedCrossRef

Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23:322–30.PubMedCrossRef

•• DuBeau CE, Kuchel GA, Johnson 2nd T, Palmer MH, Wagg A. Fourth International Consultation on Incontinence. Incontinence in the frail elderly: Report from the 4th International Consultation on Incontinence. Neurourol Urodyn. 2010;29:165–78. This report highlights important considerations when evaluating and treating UI in frail elderly. PubMedCrossRef

10.

Resnick NM, Yalla SV. Management of urinary incontinence in the elderly. N Engl J Med. 1985;313:800–5.PubMedCrossRef

11.

Wallace SA, Roe B, Williams K, Palmer M.Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2004;(1):CD001308.

12.

Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS. Weight loss: a novel and effective treatment for urinary incontinence. J Urol. 2005;174:190–5.PubMedCrossRef

13.

Aslan E, Komurcu N, Beji NK, Yalcin O. Bladder training and Kegel exercises for women with urinary complaints living in a rest home. Gerontology. 2008;54:224–31.PubMedCrossRef

14.

Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265:609–13.PubMedCrossRef

15.

Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;(4):CD003193.

16.

Godec C, Cass AS, Ayala GF. Bladder inhibition with functional electrical stimulation. Urology. 1975;6:663–6.PubMedCrossRef

17.

de Groat WC, Fraser MO, Yoshiyama M, Smerin S, Tai C, Chancellor MB, et al. Neural control of the urethra. Scand J Urol Nephrol Suppl 2001;(207):35-43; discussion 106-25.

18.

•• Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2010;1:CD005654. This systematic review and meta-analysis with rigorous methodology evaluates the efficacy of PFMT for UI in women. PubMed

19.

•• Campbell SE, Glazener CM, Hunter KF, Cody JD, Moore KN. Cochrane Database Syst Rev.. 2012;1. This systematic review and meta-analysis with rigorous methodology evaluates options such as PFMT for the management of postprostatectomy UI.

20.

Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280:1995–2000.PubMedCrossRef

21.

•• Herderschee R, Hay-Smith EJ, Herbison GP, Roovers JP, Heineman MJ. Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2011;(7):CD009252. doi:CD009252. This systematic review and meta-analysis with rigorous methodology evaluates the efficacy of biofeedback and PFMT for UI in women.

22.

Brubaker L, Benson JT, Bent A, Clark A, Shott S. Transvaginal electrical stimulation for female urinary incontinence. Am J Obstet Gynecol. 1997;177:536–40.PubMedCrossRef

23.

Alves PG, Nunes FR, Guirro EC. Comparison between two different neuromuscular electrical stimulation protocols for the treatment of female stress urinary incontinence: a randomized controlled trial. Rev Bras Fisioter. 2011;15:393–8.PubMedCrossRef

24.

Amaro JL, Gameiro MO, Kawano PR, Padovani CR. Intravaginal electrical stimulation: a randomized, double-blind study on the treatment of mixed urinary incontinence. Acta Obstet Gynecol Scand. 2006;85:619–22.PubMedCrossRef

25.

Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology. 2004;63:61–6.PubMedCrossRef

26.

Pereira VS, de Melo MV, Correia GN, Driusso P. Vaginal cone for postmenopausal women with stress urinary incontinence: randomized, controlled trial. Climacteric. 2012;15:45–51.PubMedCrossRef

27.

Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2007;4:CD003190.PubMed

28.

Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci. 2011;56:7–18.PubMedCrossRef

29.

Schiffers M, Sauermann P, Schurch B, Mehnert U. The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol 201;28:651-656.

30.

Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008;112:1311–8.PubMedCrossRef

31.

Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50:317–26.PubMedCrossRef

32.

Kessler TM, Bachmann LM, Minder C, Lohrer D, Umbehr M, Schunemann HJ, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011;6:e16718.PubMedCrossRef

33.

• Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic Drugs: Review of the Cognitive Impact When Used to Treat Overactive Bladder in Elderly Patients. Curr Urol Rep. 2011;12:351–7. This systematic review evaluates the cognitive impact of antimuscarinics in elderly. PubMedCrossRef

34.

•• Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59:1332–9. This meta-analyis highlights the need for improved measures of the impact of antimuscarinics on cognition in geriatric patients. PubMedCrossRef

35.

Sand P, Zinner N, Newman D, Lucente V, Dmochowski R, Kelleher C, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007;99:836–44.PubMedCrossRef

36.

Sand PK, Johnson Ii TM, Rovner ES, Ellsworth PI, Oefelein MG, Staskin DR. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >/= 75 years) with overactive bladder syndrome. BJU Int. 2011;107:612–20.PubMedCrossRef

37.

Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract. 2008;62:1664–74.PubMedCrossRef

38.

• Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. J Am Med Dir Assoc. 2011;12:639–47. In this trial of antimuscarinics for UUI in elderly subjects with cognitive impairment, oxybutynin did not worsen cognitive function in this 4-week trial. There was, however, no significant improvement in UUI with oxybutynin. PubMedCrossRef

39.

Gomes T, Juurlink DN, Mamdani MM. Comparative adherence to oxybutynin or tolterodine among older patients. Eur J Clin Pharmacol. 2012;68:97–9.PubMedCrossRef

40.

Gomes T, Juurlink DN, Ho JM, Schneeweiss S, Mamdani MM. Risk of serious falls associated with oxybutynin and tolterodine: a population based study. J Urol. 2011;186:1340–4.PubMedCrossRef

41.

Herschorn S, Pommerville P, Stothers L, Egerdie B, Gajewski J, Carlson K, et al. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin. 2011;27:375–82.PubMedCrossRef

42.

Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011;107:1432–40.PubMedCrossRef

43.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010;105:58–66.PubMedCrossRef

44.

Scarpero H, Sand PK, Kelleher CJ, Berriman S, Bavendam T, Carlsson M. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011;27:921–30.PubMedCrossRef

45.

Sand PK, Heesakkers J, Kraus SR, Carlsson M, Guan Z, Berriman S. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging. 2012;29:119–31.PubMedCrossRef

46.

Tyagi P, Tyagi V, Chancellor M. Mirabegron: a safety review. Expert Opin Drug Saf. 2011;10:287–94.PubMedCrossRef

47.

Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol. 2009;35:76–83.PubMedCrossRef

48.

Chapple C, Wyndaele JJ, Van Kerrebroeck P, et al. Dose-ranging study of once-daily mirabegron (Ym178), A novel selective beta3-adrenoreceptor agonist, in patients with overactive bladder (OAB) 2010;9:249.

49.

Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study(blossom) shows novel beta 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder 2008;(Abs 674):239.

50.

Elser DM. Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management. Postgrad Med. 2012;124:42–9.PubMedCrossRef

51.

Cruz F, Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol Urodyn. 2007;26:920–7.PubMedCrossRef

52.

Karsenty G, Denys P, Amarenco G, De Seze M, Game X, Haab F, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53:275–87.PubMedCrossRef

53.

Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol. 2010;58:919–26.PubMedCrossRef

54.

•• Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416–22. This randomized controlled trial has been cited as the landmark study on dosing of BoNT/A for idiopathic overactive bladder. PubMedCrossRef

55.

Bauer RM, Gratzke C, Roosen A, Hocaoglu Y, Mayer ME, Buchner A, et al. Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome. Urol Int. 2011;86:68–72.PubMedCrossRef

56.

Dowson C, Khan MS, Dasgupta P, Sahai A. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol. 2010;7:661–7.PubMedCrossRef

57.

Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2007;3:CD005493.PubMed

58.

Makovey I, Davis T, Guralnick ML, O'Connor RC. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: Lack of anticholinergic efficacy versus intolerability. Neurourol Urodyn. 2011;30:1538–40.PubMedCrossRef

59.

Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61:520–9.PubMedCrossRef

60.

•• Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367:1803–13. This trial provides Level 1 evidence for use of BoNT/A earlier in the treatment algorithim for idiopathic UUI. PubMedCrossRef

61.

Carr LK. Botulinum toxin A should not be first-line therapy for overactive bladder. Can Urol Assoc J. 2011;5:204–5.PubMedCrossRef

62.

Schaffer J, Fantl JA. Urogenital effects of the menopause. Baillieres Clin Obstet Gynaecol. 1996;10:401–17.PubMedCrossRef

63.

Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG. 2000;107:1029–34.PubMedCrossRef

64.

Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women–a double-blind placebo-controlled study. J Obstet Gynaecol. 2001;21:383–5.PubMedCrossRef

65.

Zullo MA, Plotti F, Calcagno M, Palaia I, Muzii L, Manci N, et al. Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: a randomized clinical trial. Menopause. 2005;12:421–7.PubMedCrossRef

66.

Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril. 2006;85:155–60.PubMedCrossRef

67.

MacDiarmid SA, Peters KM, Chen A, Armstrong RB, Orman C, Aquilina JW, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008;83:1002–10.PubMedCrossRef

68.

Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int. 2008;102:1133–9.PubMedCrossRef

69.

Yamaguchi O, Kakizaki H, Homma Y, Takeda M, Nishizawa O, Gotoh M, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms–ASSIST, randomized controlled study. Urology. 2011;78:126–33.PubMedCrossRef

70.

Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182:1055–61.PubMedCrossRef

71.

Kohli N, Rosenblatt PL. Neuromodulation techniques for the treatment of the overactive bladder. Clin Obstet Gynecol. 2002;45:218–32.PubMedCrossRef

72.

Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43.PubMedCrossRef

73.

Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21:1065–70.CrossRef

74.

• Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31:1206–16. This meta-analysis shows that PTNS is comparable to medication management for short-term treatment of OAB. PubMedCrossRef

75.

Occhino JA, Siegel SW. Sacral nerve modulation in overactive bladder. Curr Urol Rep. 2010;11:348–52.PubMedCrossRef

76.

Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev. 2009;2:CD004202.PubMed

77.

Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;56:87–91.PubMedCrossRef

78.

Edlund C, Dijkema HE, Hassouna MM, Van Kerrebroeck PE, Peeker R, Van den Hombergh U, et al. Sacral nerve stimulation for refractory urge symptoms in elderly patients. Scand J Urol Nephrol. 2004;38:131–5.PubMedCrossRef

79.

Amundsen CL, Webster GD. Sacral neuromodulation in an older, urge-incontinent population. Am J Obstet Gynecol. 2002;187:1462–5. discussion 1465.PubMedCrossRef

80.

White WM, Mobley 3rd JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA. Sacral nerve stimulation for refractory overactive bladder in the elderly population. J Urol. 2009;182:1449–52.PubMedCrossRef

81.

• Griebling TL. Sacral nerve stimulation in the elderly. Int Urogynecol J. 2010;21 Suppl 2:S485–9. This review reports the available data on SNM in geriatric patients. PubMedCrossRef

82.

Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol. 2006;175:835–41.PubMedCrossRef

83.

Fujishiro T, Takahashi S, Enomoto H, Ugawa Y, Ueno S, Kitamura T. Magnetic stimulation of the sacral roots for the treatment of urinary frequency and urge incontinence: an investigational study and placebo controlled trial. J Urol. 2002;168:1036–9.PubMedCrossRef

84.

McFarlane JP, Foley SJ, de Winter P, Shah PJ, Craggs MD. Acute suppression of idiopathic detrusor instability with magnetic stimulation of the sacral nerve roots. Br J Urol. 1997;80:734–41.PubMedCrossRef

85.

But I, Faganelj M, Sostaric A. Functional magnetic stimulation for mixed urinary incontinence. J Urol. 2005;173:1644–6.PubMedCrossRef

86.

Wallis MC, Davies EA, Thalib L, Griffiths S. Pelvic static magnetic stimulation to control urinary incontinence in older women: a randomized controlled trial. Clin Med Res. 2012;10:7–14.PubMedCrossRef

87.

•• Lipp A, Shaw C, Glavind K. Mechanical devices for urinary incontinence in women. Cochrane Database Syst Rev 2011;(7):CD001756. This systematic review and meta-analysis with rigorous methodology evaluates the efficacy of mechanical devices for UI in women.

88.

Moore KN, Schieman S, Ackerman T, Dzus HY, Metcalfe JB, Voaklander DC. Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. Urology. 2004;63:150–4.PubMedCrossRef

89.

Vaughan CP, Goode PS, Burgio KL, Markland AD. Urinary incontinence in older adults. Mt Sinai J Med. 2011;78:558–70.PubMedCrossRef

90.

Griebling T. Geriatric urology In: Solomon DH, LoCicero L, Rosenthal R (eds) New Frontiers in Geriatric Research. American Geriatric Society, 2004. pp 269-302.

91.

Monga AK, Robinson D, Stanton SL. Periurethral collagen injections for genuine stress incontinence: a 2-year follow-up. Br J Urol. 1995;76:156–60.PubMedCrossRef

92.

Ghoniem G, Corcos J, Comiter C, Westney OL, Herschorn S. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol. 2010;183:1444–9.PubMedCrossRef

93.

Herschorn S, Bruschini H, Comiter C, Grise P, Hanus T, Kirschner-Hermanns R, et al. Surgical treatment of stress incontinence in men. Neurourol Urodyn. 2010;29:179–90.PubMedCrossRef

94.

Ku JH, Oh JG, Shin JW, Kim SW, Paick JS. Age is not a limiting factor for midurethral sling procedures in the elderly with urinary incontinence. Gynecol Obstet Invest. 2006;61:194–9.PubMedCrossRef

95.

Kim J, Lucioni A, Govier F, Kobashi K. Worse long-term surgical outcomes in elderly patients undergoing SPARC retropubic midurethral sling placement. BJU Int. 2011;108:708–12.PubMedCrossRef

96.

Albo ME, Richter HE, Brubaker L, Norton P, Kraus SR, Zimmern PE, et al. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med. 2007;356:2143–55.PubMedCrossRef

97.

Comiter CV. Male incontinence surgery in the 21st century: past, present, and future. Curr Opin Urol. 2010;20:302–8.PubMedCrossRef

98.

Blaganje M, Lukanovic A. Intrasphincteric autologous myoblast injections with electrical stimulation for stress urinary incontinence. Int J Gynaecol Obstet. 2012;117:164–7.PubMedCrossRef

99.

•• Vinsnes AG, Helbostad JL, Nyronning S, Harkless GE, Granbo R, Seim A. Effect of physical training on urinary incontinence: a randomized parallel group trial in nursing homes. Clin Interv Aging. 2012;7:45–50. This trial highlights the importance of treating co-existing conditions, specifically decreased activities of daily living, to improve UI. PubMedCrossRef

Title: Urinary Incontinence: Diagnosis and Treatment in the Elderly
Authors: Joy A. Greer
Lily A. Arya
Ariana L. Smith
Publication date: 01-06-2013
Publisher: Current Science Inc.
Published in: Current Geriatrics Reports / Issue 2/2013
Electronic ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-013-0037-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Management of Severe Osteoporosis in Primary Total Hip Arthroplasty

Late Onset Hypogonadism, Testosterone Replacement Therapy, and Sexual Health in Elderly Men

Outcomes of Minimally Invasive Urologic Surgery in the Elderly Patient Population

Perioperative Assessment of Elderly Surgical Patients

Medical Management of Osteoporosis When Bisphosphonates Fail

The Utility of Prostate-Specific Antigen Screening and Prostate Cancer Treatment in Elderly Patients

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage